Mobile

An investigational study to assess the safety and efficacy of a new investigational drug in subjects with compensated liver cirrhosis secondary to non-alcoholic steatohepatitis (NASH)

Update Il y a 5 ans
Reference: EUCTR2012-002489-11

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate whether simtuzumab (formerly referred to as GS-6624) can reduce portal venous pressure and incidence of clinical events in subjects with cirrhosis due to NASH.

Inclusion criteria

  • Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Links